Skip to main
BTSG

BTSG Stock Forecast & Price Target

BTSG Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrightSpring Health Services Inc. is demonstrating robust growth, particularly in its OP Rehab segment, which is generating attractive margins and is projected to enhance EBITDA significantly through improved margins and strategic mergers and acquisitions. The company’s focus on generic drug conversions is expected to sustain strong EBITDA growth, supported by anticipated wins in the low double digits (LDD) and operational initiatives, contributing to increased market share in the specialty pharmacy sector. Management’s visibility into generic conversions further reinforces a positive outlook for the company’s financial performance and growth trajectory through 2026 and beyond.

Bears say

BrightSpring Health Services Inc. faces potential revenue challenges due to the vulnerability of client budgets, which may adversely impact its business dynamics. The company's significant reliance on its Pharmacy Solutions segment raises concerns, especially if healthcare professionals reduce prescriptions or if drug utilization decreases, potentially leading to diminished cash flows and operating results. Furthermore, BrightSpring's heavy debt burden may constrain its capacity for growth investments, limiting its expansion opportunities within the competitive healthcare market.

BTSG has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BrightSpring Health Services Inc (BTSG) Forecast

Analysts have given BTSG a Buy based on their latest research and market trends.

According to 9 analysts, BTSG has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BrightSpring Health Services Inc (BTSG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.